Ian Ingram

3-year survival twice as high with mRNA vaccine in lung cancer patients receiving immunotherapy

Along with EFS benefit, adding durvalumab to perioperative chemotherapy significantly improved OS

TNF inhibitors don't always have to go before upadacitinib, agency says

In placebo-controlled trials, nerandomilast significantly slowed decline in forced vital capacity

News and commentary from the world of gastroenterology and hepatology

Oral Drug Wins FDA Approval for Chronic Hives

Agency published new batch of 89 letters, promises to start posting them in real time

News and commentary from the world of gastroenterology and hepatology

GLP-1 Drugs May Hold Benefit in Painful Skin Disease

DPP-1 inhibitor brensocatib approved for non-cystic fibrosis bronchiectasis

News and commentary from the world of gastroenterology and hepatology

First aceclidine-based ophthalmic solution to get agency blessing for presbyopia

News and commentary from the world of gastroenterology and hepatology

News and commentary from the world of gastroenterology and hepatology

First Targeted Drug Approved for Blistering Skin Condition

News and commentary from the world of gastroenterology and hepatology

News and commentary from the world of gastroenterology and hepatology

CAN-2409 plus valacyclovir also had a manageable safety profile alongside standard radiotherapy

PAXG improved event-free survival versus mFOLFIRINOX in resectable/borderline resectable tumors

PFS improved for patients with emerging ESR1 mutations when they switched to novel oral SERD